Financial results - OITUZ PHARMA SRL

Financial Summary - Oituz Pharma Srl
Unique identification code: 34635334
Registration number: J04/607/2015
Nace: 4773
Sales - Ron
257.414
Net Profit - Ron
32.233
Employee
3
The most important financial indicators for the company Oituz Pharma Srl - Unique Identification Number 34635334: sales in 2023 was 257.414 euro, registering a net profit of 32.233 euro and having an average number of 3 employees. Firma isi desfasoara activitatea in domeniul Comert cu amanuntul al produselor farmaceutice, in magazine specializate having the NACE code 4773.

Sales, Profit, Employees, Debts, Capitals, Financial Results - Oituz Pharma Srl

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Sales - EUR - 7.596 56.590 89.116 119.321 133.726 176.904 199.076 262.528 257.414
Total Income - EUR - 7.596 56.590 89.120 119.323 133.790 176.924 199.093 262.532 257.415
Total Expenses - EUR - 12.044 52.334 84.543 106.081 113.694 147.441 164.511 220.960 222.992
Gross Profit/Loss - EUR - -4.448 4.256 4.577 13.241 20.096 29.483 34.582 41.572 34.423
Net Profit/Loss - EUR - -4.676 3.690 3.686 12.048 18.758 27.844 32.631 39.055 32.233
Employees - 1 2 2 2 2 2 2 3 3
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity. The data show the company's evolution during this period, highlighting any increases or potential decreases recorded. In the last year of activity, the sales decreased by -1.6%, from 262.528 euro in the year 2022, to 257.414 euro in 2023. The Net Profit decreased by -6.703 euro, from 39.055 euro in 2022, to 32.233 in the last year.

Check the financial reports for the company - Oituz Pharma Srl

Rating financiar

Financial Rating -
Oituz Pharma Srl

See the company's note based on the submitted financial data, relative to the industry of which it is a part.

Check Financial Rating
Limite de plata

Payment Limits -
Oituz Pharma Srl

See the company's payment capacity for situations in which you conclude contracts with payment terms.

Check Payment Limits
Probabilitate de insolventa

Prob. of insolvency -
Oituz Pharma Srl

It determines the risk of insolvency based on the submitted accounting balance.

Check Insolvency Probability
Rapoarte financiare

Financial Reports -
Oituz Pharma Srl

Check all the financial reports of the company and know the risks in collaboration with it.

Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.

Debts, Equity, Inventories, Receivables, Accounts, Assets - Oituz Pharma Srl - CUI 34635334

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Fixed Assets - 2.045 1.450 1.082 822 938 1.944 1.680 1.896 1.398
Current Assets - 6.821 14.348 15.769 30.057 42.755 72.422 107.473 119.359 154.400
Inventories - 6.536 12.496 8.803 12.297 12.132 20.079 23.510 22.449 35.492
Receivables - 0 0 4.791 5.024 4.231 7.910 11.367 22.452 13.345
Cash - 285 1.852 2.175 12.736 26.391 44.433 72.596 74.458 105.563
Shareholders Funds - -4.631 -893 2.808 14.804 33.276 60.489 91.778 98.470 130.405
Social Capital - 45 45 44 43 42 41 40 41 40
Debts - 13.496 16.691 14.043 16.075 10.417 13.878 17.376 22.785 25.393
Income in Advance - 0 0 0 0 0 0 0 0 0
Exchange rate - RON 4.9465 4.9315 4.9468 4.8371 4.7454 4.6535 4.5681 4.4908 4.445 4.4821
Main CAEN "4773 - 4773"
CAEN Financial Year 4773
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of 154.400 euro in 2023 which includes Inventories of 35.492 euro, Receivables of 13.345 euro and cash availability of 105.563 euro.
The company's Equity was valued at 130.405 euro, while total Liabilities amounted to 25.393 euro. Equity increased by 32.233 euro, from 98.470 euro in 2022, to 130.405 in 2023.

Activate the Financial Reports subscription with unlimited access and check the evolution and current financial situation of any company.

Subscriptions Financial Reports

You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.

Subscription cost is per user. You can pay simultaneously up to 10 users.
RisCo Subscriptions offer the greatest flexibility in choosing the best services according to the needs of each user. These are structured into categories based on the type of service desired, as well as on different service contract periods: monthly, semi-annually, and annually. Check out the subscription offer for the best choices!

Reviews - Oituz Pharma Srl

Comments - Oituz Pharma Srl

Similar services useful for checking companies and business development.

Contacts Firms

Get the contact details for any company and get in touch with it.

Sectoral Studies

Knows the market and develops its own development strategies according to sectorial data.

Company Lists

Create lists of companies for your sales activity according to your own criteria.

Import - Export

Find importers and exporters according to the type of activity and the countries in which they carry it out.

Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.